Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

GENE - CHEMICAL INTERACTIONS REPORT

RGD ID: 2218
Species: Rattus norvegicus
RGD Object: Gene
Symbol: Brca1
Name: BRCA1, DNA repair associated
Acc ID: CHEBI:27899
Term: cisplatin
Definition: A diamminedichloroplatinum compound in which the two ammine ligands and two chloro ligands are oriented in a cis planar configuration around the central platinum ion. An anticancer drug that interacts with, and forms cross-links between, DNA and proteins, it is used as a neoplasm inhibitor to treat solid tumours, primarily of the testis and ovary. Commonly but incorrectly described as an alkylating agent due to its mechanism of action (but it lacks alkyl groups).
Chemical ID: MESH:D002945
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction is comprised of a complex set of reactions and/or regulatory events, possibly involving additional chemicals and/or gene products.
Object SymbolQualifierEvidenceWithReferenceSourceNotesOriginal Reference(s)
Brca1decreases activityISOBRCA1 (Homo sapiens)6480464CTDCisplatin results in decreased activity of BRCA1 proteinPMID:20878461
Brca1decreases response to substanceISOBrca1 (Mus musculus)6480464CTDBRCA1 results in decreased susceptibility to CisplatinPMID:21771338
Brca1decreases response to substanceISOBRCA1 (Homo sapiens)6480464CTDBRCA1 protein results in decreased susceptibility to Cisplatin; BRCA1 results in decreased susceptibility to CisplatinPMID:20603439 PMID:21633166 PMID:21854619
Brca1increases expressionISOBrca1 (Mus musculus)6480464CTDCisplatin results in increased expression of BRCA1 mRNAPMID:21151649
Brca1increases expressionISOBRCA1 (Homo sapiens)6480464CTDCisplatin results in increased expression of BRCA1 mRNA; Cisplatin results in increased expression of BRCA1 proteinPMID:20623183 PMID:27594783
Brca1increases phosphorylationISOBrca1 (Mus musculus)6480464CTDCisplatin results in increased phosphorylation of BRCA1 proteinPMID:22006019
Brca1multiple interactionsISOBRCA1 (Homo sapiens)6480464CTD[Cisplatin results in decreased susceptibility to Cisplatin] which results in increased expression of BRCA1 mRNA; BRCA1 mutant form promotes the reaction [RRM2 mutant form promotes the reaction [TP53 mutant form promotes the reaction [Cisplatin results in increased activity of and results in increased phosphorylation of CHEK1 protein]]]; BRCA1 mutant form promotes the reaction [RRM2 mutant form promotes the reaction [TP53 mutant form promotes the reaction [Cisplatin results in increased phosphorylation of H2AX protein]]]; BRCA1 mutant form promotes the reaction [RRM2 mutant form promotes the reaction [TP53 mutant form results in increased susceptibility to Cisplatin]]; ESR2 protein inhibits the reaction [Cisplatin results in increased expression of BRCA1 mRNA]; ESR2 protein inhibits the reaction [Cisplatin results in increased expression of BRCA1 protein]; Vorinostat inhibits the reaction [BRCA1 results in decreased susceptibility to Cisplatin]PMID:20623183 PMID:21854619 PMID:21875941 PMID:30871063
Go Back to source page   Continue to Ontology report